SUMMARY -Th e objective of this study was to determine diff erential expression of TFF1, TFF2 and TFF3 genes and proteins in breast tumor subtypes. In addition, we investigated the correlation between TFF genes within tumor subgroups, and TFF genes with clinical and pathologic characteristics of the tumor. Study group included 122 patients with surgically removed breast tumors. Samples were investigated using qRT-PCR and immunohistochemistry. TFF1 and TFF3 genes and proteins were expressed in breast tumors, while the levels of TFF2 gene and protein expression were very low or undetectable. TFF1 was signifi cantly more expressed in benign tumors, while TFF3 was more expressed in malignant tumors. Gene and protein expression of both TFF1 and TFF3 was greater in lymph node-negative tumors, hormone positive tumors, tumors with moderate levels of Ki67 expression, and in grade II tumors. A strong positive correlation was found between TFF1 and TFF3 genes, and the expression of both negatively correlated with Ki67 and the level of tumor histologic diff erentiation. Our results suggest that TFF1 and TFF3, but not TFF2, may have a role in breast tumor pathogenesis and could be used in the assessment of tumor diff erentiation and malignancy.
Introduction
Breast cancer is the most common form of cancer aff ecting women worldwide, and is a global health, economic and social problem 1 . Malignant breast tumors are a highly heterogeneous tumor group and are therefore diffi cult to classify into uniform subgroups that could be used to assess malignancy of the tumor, choose appropriate treatment, and thus ensure longterm survival of patients 2 . According to St. Gallen consensus, which is based on estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2) expression, tumors are divided into four subgroups: Luminal A (Lum A), Luminal B (Lum B), HER2 positive (HER2 pos) and triple negative (triple neg) 3 . Th is consensus can apply to all types of breast tumors regardless of their histologic type and is of substantial clinical signifi cance because it helps assess tumor malignancy and select ap-propriate treatment 4 . However, breast tumors still exhibit substantial histologic and clinical heterogeneousness. Th erefore, new biomarkers are needed to improve diagnosis, assess progression of the disease and choose appropriate tumor therapy to ease treatment and prolong patient survival 5 . Trefoil factor family (TFF) proteins are small secretory proteins expressed mainly in the gastrointestinal tract, but are also found in many other human tissues. Th e trefoil factor family consists of three members (TFF1, TFF2 and TFF3) expressed in diff erent human tissues 6, 7 . TFF proteins participate in numerous physiologic and pathologic processes through different mechanisms. Th eir versatile functions are important in mucosal restitution and repair processes, cell adhesion, motility, apoptosis, and angiogenesis [8] [9] [10] . Th ey are also found in diff erent tissues during embryonic development 11 . Apart from healthy tissues, TFF proteins are expressed in various pathologically changed tissues, such as infl amed gut in the infl ammatory bowel disease and malignant tumors, including breast cancer 12 . Th ere is a controversy regarding the impact of TFF1 protein on the malignant properties of breast cancer. Some studies indicate that it enhances breast cancer development [13] [14] [15] [16] , whereas others propose a tumor-suppressive role [17] [18] [19] [20] . At fi rst, TFF2 protein was not found in the epithelium of either normal or pathologically changed breasts 21 . Later experiments have revealed that TFF2 protein is expressed in breast cancer cell line, both in normal breast cells and in breast tumor cells, and has a motogenic eff ect on breast cancer cells in cell culture; however, it is secreted in very small amounts compared to TFF1 and TFF3 proteins 22 . According to experiments on breast cancer cell lines, TFF2 protein is considered a negative prognostic biomarker [23] [24] [25] . Past studies of TFF3 protein have indicated that it promotes invasiveness, prevents apoptosis of tumor cells, and stimulates neoangiogenesis in tumor tissue, allowing tumor progression and promoting its malignancy. TFF3 protein has been therefore categorized as a biomarker indicating poor prognosis, even though it is expressed more strongly in hormone receptor-positive tumors, which have better prognosis 9, [26] [27] [28] [29] . Th e objective of this study was to determine differential expression of TFF genes and TFF proteins in various breast tumor subtypes. Additionally, we assessed correlation between TFF genes within the tumor subgroups and their correlation with the clinical and pathologic characteristics of the tumor in order to determine their value as potential biomarkers.
Our results suggested that TFF1 and TFF3, unlike TFF2, may have a role in breast tumor pathogenesis and could be used in the assessment of tumor malignancy only in particular breast tumor subgroups. Increased expression of TFF1 could be used as a potential biomarker indicating good prognosis, whereas TFF3 could be helpful in tumor status assessment.
Patients and Methods

Study population
Th e study included 122 female patients that underwent surgery at the Department of Surgery, Osijek University Hospital Centre for obvious breast tumor. Th e study lasted for 30 months (2014-2016) . Th e test group comprised of 91 surgical patients with malignant breast tumors and 31 patients with fi broadenomas (benign breast tumors) surgically removed 30 . On analyzing the data obtained, we subdivided the malignant group depending on hormone receptor status (2011 St. Gallen consensus) 4 , histologic grade (Nottingham Grading System) 31 , aff ectio n of lymph nodes by metastases, and levels of expression of the Ki67 proliferation marker.
Gene analysis
Tumor samples for gene expression analysis were obtained during surgical procedures and were immediately stored in the RNAlater® total RNA integrity preservation solution (Applied Biosystems, USA). Th e collected samples were kept at room temperature for one hour and afterwards stored at -80 °C until total RNA isolation process.
Tissue samples were homogenized with liquid nitrogen. Total RNA isolation was performed using the TRI Reagent (Life Technologies, USA) according to the manufacturer's protocol. Total RNA was diluted with 30 μL of DEPC-treated water (Santa Cruz, USA) and stored at -80 °C. Amplifi cation Grade DNase I (Sigma-Aldrich, USA) commercial kit was used to remove DNA molecules from RNA samples, following the manufacturer's protocol. NanoPhotometer® P-Class P330-30 micro volume spectrophotometer (Implen, Germany) was used to determine RNA concentration and sample purity. Isolated RNA was transcribed into cDNA using reverse transcriptase from the PrimeScriptTM RT reagent Kit (Perfect Real Time, Takara, USA) commercial kit. Th e reaction was performed in a CFX96 device (Bio Rad, USA) for 120 minutes at 37 °C, followed by 5 seconds at 85 °C. Th e reaction mixture was then cooled to 4 °C.
Nucleotide sequences for the primers were chosen using the primer designing program available on the website http://eu.idtdna.com/site and literature 32 . Optimal reaction c onditions in which an effi ciency ranging from 95% to 100% was achieved were determined for each individual gene primer pair. Each sample was processed in duplicate. qRT-PCR reactions were performed in the following conditions: enzyme activation at 95 °C for 30 seconds followed by 40 cycles of denaturation at 95 °C for 5 seconds, primer annealing at 55-60 °C for 5 seconds (40 cycles) and 10 seconds at 55-63 °C, with the fi nal disassociation step. qRT-PCR was performed on a Real Time PCR System Bio Rad CFX96 device. Actin beta (ACTB) gene expression was used to normalize gene expression 33 . Primer sequences and annealing temperature used for qRT-PCR analysis are presented in Table 1 .
Protein analysis
Protein expression was accompanied by immunohistochemical sample analysis. Th e patient cohort comprised of 75 surgical patients with breast tumors removed, 15 (20%) of which were fi broadenoma samples (benign tumors) and 60 (80%) malignant tumor samples. All samples were collected at the Department of Pathology and Forensic Medicine, Osijek University Hospital Centre. All samples were subjected to an initial histopathologic analysis and were histopathologically reconfi rmed by an independent pathologist. Formalin-fi xed and paraffi n-embedded sections of breast tumor tissue were deparaffi nized and rehydrated. Endogenous peroxidase blocking using 0.3% hydrogen peroxide (15 minutes) was performed on the sections, followed by antigen retrieval in citrate buff er (pH=6.0) by heating in a microwave oven for 5 minutes. Th e primary antibody was applied to the slides, and incubated at 4 °C overnight. Primary antibodies used in this study were anti-TFF1 (Anti-Estrogen Inducible Protein pS2 antibody ab92377, Abcam, USA), anti-TFF2 (Anti-Spasmolytic Polypeptide antibody ab131147, Abcam, USA) and anti-TFF3 (purifi ed polyclonal rabbit anti-TFF3 antibody, proprietary, self-made) 34 . Negative controls were incubated with phosphate-buff ered saline (PBS, pH=7.4) instead of primary antibody. Human stomach tissue was used as positive control for TFF1 and TFF2 proteins, and human colon tissue was used as positive control for TFF3 protein. Following primary antibody incubation, the sections were washed in PBS with Tween (0.05%) (Sigma Aldrich, USA) four times. Th is was followed by application of secondary antibody (affi nity purifi ed, biotinylated goat anti-rabbit IgG, Vector Laboratories, USA), left at room temperature for 120 minutes. Th is procedure was followed by four more washes in PBS with 0.05% Tween, after which the slides were incubated with streptavidin conjugated to horseradish peroxidase (Streptavidin-HRP, Vector Laboratories, USA) at room temperature for 45 minutes. After four more washes in PBS with Tween, 3.3'-diaminobenzidine solution was applied (DAB Peroxidase (HRP) Substrate Kit, Vector Laboratories, USA). After four Th e slides thus obtained were analyzed by two independent histologists. Th ey were photographed using an Olympus® C-5050 digital camera connected to an Olympus® BX-50 microscope and QuickPHOTO Pro software. Th e histomorphological analysis determined the existence, proportion and signal strength of TFF protein expression in individual samples using the Modifi ed Quick Score (Q) method of immunohistochemical staining 35, 36 . Modifi ed Quick Score method is presented in Table 2 .
used for correlation assessment. All p-values were twosided. Materiality level was set to α=0.05. MedCalc statistical software (version 16.2.0, MedCalc Software bvba, Ostend, Belgium) was used on statistical analysis. GraphPad Prism software (version 6, GraphPad Software, Inc., USA) was used to make the fi gures.
Compliance with ethical standards
An informed consent was obtained from all patients included in the study. Th e study obtained approval from local ethics committees, the Ethics Committee of the Osijek University Hospital Centre 
Results
Patient population and clinicopathologic characteristics
Th e study included 122 patients, age median 62 years (interquartile range 45-74 years), ranging from 18 to 88 years of age. Th irty-one (25%) patients had benign tumor (fi broadenomas) and 91 (75%) had malignant tumor. Th e subjects with malignant tumors were considerably older, age median 68 years (interquartile range 57-76 years; p<0.001). Body mass index (BMI) was considerably higher in the group of subjects with malignant tumors as compared to subjects with benign tumors (fi broadenoma). Within the malignant group, 78 (85.7%) tumors were hormone receptor-positive and 13 (14.3%) tumors were hormone receptor-negative. According to the St. Gallen consensus, there were 20 (22%) Lum A, 58 (63.7%) Lum B, 4 (4.4%) Her 2 positive and 9 (9.9%) triple negative tumors (Table 3) . Within the malignant group, 50 (54.9%) subjects had metastases in lymph nodes, whereas 41 (45.1%) subjects did not have metastases in lymph nodes. Histologic diff erentiation grade, Ki67 level of expression and other pathologic characteristics of the samples are presented in Table 3 .
TFF gene expression
Th e expression of TFF1 mRNA was substantially higher in the benign tumor group consisting of subjects with fi broadenomas compared to subjects from 
Statistical methods
Sample size was defi ned based on preliminary research results. A minimum sample size of 22 subjects per group or 44 subjects in 2 groups was required to detect a 0.4 eff ect with α=0.05 and test strength of 0.8. Category data was presented in absolute and relative frequencies. Numerical data were described by median and interquartile range limits. Th e χ 2 -test and, where necessary, Fisher exact test were used to test category variable diff erences. Th e Shapiro-Wilk test was used to test the normality of numeric variable distribution. Th e Mann-Whitney U test was used to test numeric variable diff erences due to deviations from normal distribution. Spearman's rank correlation coeffi cient was the malignant group (p=0.048) (Fig. 1, panel A) . Our study revealed a very low level of TFF2 mRNA expression in benign breast tumors and extremely low TFF2 expression in malignant breast tumors, thus TFF2 was not expressed (Fig. 7, panel A) . TFF3 mRNA expression was higher in the malignant tumor group, but statistically signifi cant diff erence was not noted (p=0.44) (Fig. 1, panel A) . Within the malignant group, both TFF1 and TFF3 were expressed more strongly in the hormone receptor-positive tumor group (Fig. 1, panel B) , but only TFF3 exhibited a statistically signifi cant mRNA expression diff erence (p=0.004) (Fig. 1, panel B) . Comparing the results between the groups defi ned according to St. Gallen consensus, we found that TFF1 was expressed most strongly in Lum A subgroup and TFF3 was most (Fig. 1, panel C) . TFF1 and TFF3 expression was higher in subjects with tumors that did not have metastases in lymph nodes (Fig. 1,  panel D) . Strong positive correlation between TFF1 and TFF3 was recorded within the malignant tumor group (p<0.001; ρ=0.731) (Fig. 2, panel A) and it was even more prominent in the hormone receptor-positive malignant tumor subgroup (p<0.001; ρ=0.747) (Fig. 2,  panel B) .
Comparing the results between the malignant subgroups defi ned according to tumor histologic diff erentiation grade, a signifi cant diff erence in the expression of TFF1 and TFF3 mRNA was observed. Th e moderately diff erentiated tumor subgroup (grade II) had the highest TFF1 and TFF3 expression, while the poorly diff erentiated tumor group (grade III) had the lowest expression (p=0.008 and p=0.001, respectively) (Fig. 3,  panel A) . Strong positive correlation between TFF1 and TFF3 was found in all three subgroups defi ned by tumor histologic diff erentiation grade, but was strongest in well-diff erentiated tumors (grade I) (p<0.001; ρ=0.770) (Fig. 2, panel C) .
When classifying malignant tumors according to the level of Ki67 expression, the highest expression of TFF1 and TFF3 was measured in the group of tumors with moderately high expression of Ki-67 (Fig. 3, panel B) . Even though the results did not yield a statistically signifi cant diff erence in mRNA expression between the subgroups, a mild negative correlation was observed for Ki67 with TFF1 and TFF3 in the malignant group. As Ki67 expression increased, the expression of TFF1 (p=0.028; ρ=-0.248) (Fig. 4, panel A) and TFF3 (p=0.011; ρ=-0.285) (Fig. 4, panel B) decreased signifi cantly. Th e most prominent correlation was recorded between Ki67 and TFF3 in the hormone receptor-negative tumor subgroup (p=0.03; ρ=-0.629) (Fig. 4, panel C) . 

Fig. 2. Correlation between TFF1 and TFF3 mRNA expression within the malignant group (panel A); hormone receptor-positive (HR+) and hormone receptor-negative (HR-) malignant tumor subgroups (panel B); and malignant tumor subgroups defi ned by histologic diff erentiation grade: I (good), II (moderate) and III (poor) (panel C). Strong positive correlation was
TFF protein expression
Th e immunohistochemical signal of TFF1 and TFF3 proteins was visible in the cytoplasm of tumor cells and there was no evidence of nuclear immunoreaction (Fig. 5) . TFF1 protein expression was higher in the benign tumor group (p<0.001) (Fig. 6, panel A) , whereas TFF3 protein expression was higher in the malignant tumor group (p<0.001) (Fig. 6, panel A) . None of the tumor tissue subgroups, irrespective of malignancy, exhibited TFF2 protein expression (Fig. 7,  panel B) . Comparing the results between the subgroups defi ned according to the St. Gallen consensus, Lum A and Lum B tumor subgroups had the highest TFF1 protein expression (p<0.001) (Fig. 5, TFF1; Fig.  6, panel B) . TFF3 protein expression was highest in Lum B tumor subgroup (p<0.001) (Fig. 5, TFF3; Fig.   6, panel B) . Th e Her2 positive and triple negative tumor subgroups had the lowest expression of both TFF1 and TFF3 proteins.
Discussion
In the present study, we examined the expression of all three TFF genes and TFF proteins in breast tumor tissue and compared them according to tumor malignancy, diff erentiation grade, marker of cell proliferation (Ki67), and tendency to produce metastases in axillary lymph nodes. Expression of TFF genes was measured by qRT-PCR from total RNA isolated from tissue samples which had heterogeneous cell population; to make sure that the vast amount of measured mRNA was from tumor tissue, protein products of those genes were located by immunohistochemistry. Correlations between TFF within the tumor subgroups, and correlations of TFF with Ki67 and tumor diff erentiation grade were also examined.
Fig. 3. Distribution of TFF1 and TFF3 mRNA expression depending on histologic tumor grade diff erentiation: good (I), moderate (II) and poor (III) (panel A) and depending on the expression of proliferation marker Ki67 (%): low, moderate and high (panel B) within the malignant group of breast tumors. Th e test group comprised of 91 surgically removed malignant human breast tumors. Relative mRNA expression was measured by qRT-PCR; all measured genes were normalized to expression of Actin beta (ACTB) gene. Data are presented as median and interquartile
TFF1
Many in vitro and in vivo studies of TFF1 gene and TFF1 protein have been performed in the past, however, scientists have not yet agreed about the role of TFF1 protein in tumor tissue, and whether its action is pro-oncogenic or protective.
Th is study showed that TFF1 levels were higher in the benign group (fi broadenomas) compared to malignant tumors. When TFF1 levels were compared between malignant tumor subgroups defi ned by the St. Gallen consensus, we found the highest TFF1 expression in Lum A and Lum B groups, both hormone receptor-positive tumors, which have a higher survival rate than hormone receptor-negative tumors 37 . In the subgroups according to the lymph node status, TFF1 levels were higher in tumors without metastases in lymph nodes, also characterized by higher survival rate 38 . Our fi ndings are in line with the results from several previous studies indicating a high level of TFF1 gene expression in breast tumors as a biomarker of good prognosis, in spite of the fact that diff erent molecular methods and diff erent tumor classifi cations and models were used 18, 19 . Th e study by Buache et al. demonstrated that TFF1 knock-out mice had a higher incidence and larger mammary cancers than wild-type mice, and in vitro experiment, performed in the same study, on estrogen receptor-positive and estrogen receptor-negative cell lines showed that TFF1 protein did not have oncogenic qualities 18 . Similarly, the study by Corte et al. showed that high cytosolic levels of TFF1 were associated with better clinical outcome and prolonged overall survival 19 . Even though the expression of TFF1 mRNA in our study was highest in tumors with moderately high Ki67 expression, the lowest values were measured in the tumor subgroup with high expression of Ki67. Results of TFF1 protein expression refl ected our fi ndings on the TFF1 gene expression analysis. Additionally, analysis of the correlation between TFF1 gene and Ki67 showed that the expression of TFF1 decreased as Ki67 increased. Such fi ndings support the thesis that the higher expression of TFF1 means better prognosis for breast tumor patients, as it is known that the malignancy of a tumor increases as Ki67 increases 39 .
TFF2
Our results showed a very low level of TFF2 mRNA expression in benign breast tumor samples and almost no expression in malignant breast tumors. Consistently, immunohistochemical analysis did not reveal TFF2 protein expression in a single sample. Our results are in accordance with the results of several previous studies that detected TFF2 gene expression in breast tumor cell lines, but not in human tissue 22, 23, 40 . Th e observed diff erence between in vivo and in vitro experiments could be due to the greater number of parameters infl uencing regulation, expression and role of TFF2 gene and protein in in vivo conditions. Based on our fi ndings, TFF2 gene and TFF2 protein have very poor potential as biomarkers for breast tumor assessment.
TFF3
In this study, TFF3 was expressed in all tumor samples, but the highest expression was found in malignant tumors, unlike TFF1, which was highly expressed in benign tumors (fi broadenomas). Th e highest level of TFF3 expression among the malignant tumor subgroups (defi ned according to St. Gallen consensus) was in Lum B group, which is a hormone receptor-positive tumor subgroup. Additionally, the highest level of TFF3 expression was detected in grade I and grade II tumors, which conforms to the studies by Ahmed et al. and May and Westley, who found that TFF3 expression was higher in grade I tumors and in tumors with estrogen and progesterone receptor expression 26, 43 . When the expression was compared among the subgroups with diff erent levels of Ki67 expression, the highest TFF3 expression was observed in the tumor subgroup with moderately high Ki67 expression. Th e TFF3 mRNA levels were higher in tu- 26, 29 . Th e study by Ahmed et al., based on multivariate binary logistic regression analysis of several clinicopathologic features and molecular biomarkers, concluded that the higher expression of TFF3 protein could be a metastatic tumor dissemination predictor 26 . Similarly, Pandey et al. conclude, based on TFF protein analysis in breast tumors, that the TFF3 protein expression is signifi cantly associated with lymph node metastasis and stimulates cellular invasion, and is therefore a metastatic tumor dissemination predictor 29 . Strong positive correlation between TFF1 and TFF3, especially in tumors with a lower degree of malignancy, are consistent with the fi ndings that TFF1 and TFF3 have the same controlling mechanisms, such as estrogen responsiveness 41, 42 . Our fi ndings of negative correlation between TFF3 and Ki67 and positive correlation between TFF3 and TFF1 in hormone receptor-negative tumors suggested that the patients diagnosed with hormone receptornegative tumors with high levels of TFF3 expression could also benefi t from endocrine therapy because it is known that both TFF1 and TFF3 genes are regulated by estrogen 41, 42 . Th is is further supported in the study by May and Westley, showing that TFF3 expression is an independent predictive biomarker of both estrogen response and degree of response 43 . Consistently to previous fi ndings, we demonstrated that the expression of TFF3 protein corresponded to the TFF3 mRNA expression. In this study, we demonstrated the presence of TFF1 and TFF3 mRNA and their corresponding protein products in the investigated breast tumors with variable expression levels among diff erent tumor subgroups, while the TFF2 mRNA and TFF2 protein levels were low or undetectable. Our results suggest that TFF1 and TFF3, unlike TFF2, may have a role in breast tumor pathogenesis and could be used in the assessment of tumor malignancy only in particular breast tumor subgroups. Increased expression of TFF1 could be used as a potential biomarker indicating a good prognosis, while TFF3 could be helpful in tumor status assessment; however, additional in vivo studies are needed to reach an agreement on the exact clinical impact of TFF molecules and their activity in breast tumor tissues. 
Fig. 6. Distribution of TFF1 and TFF3 protein expression in benign (B) and malignant (M) breast tumors (panel A) and malignant tumor subgroups according to St. Gallen consensus (panel B
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